Search Results 111-120 of 14713 for infliximab

  1. A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis - Mayo Clinic

    methotrexate [MTX]), immunomodulators, and/or tumor necrosis factor alpha (TNF-?) antagonist therapy (eg, infliximab, adalimumab). This includes ...

  2. Psoriatic arthritis - Diagnosis & treatment - Mayo Clinic

    Biologic agents include adalimumab (Humira), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), ustekinumab (Stelara) ...

  3. Etanercept-szzs (subcutaneous route) - Mayo Clinic

    Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus Vaccine, Live; Poliovirus Vaccine, Live; Rilonacept; Rotavirus Vaccine, Live ...

  4. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Mayo Clinic

    8 week washout for infliximab or adalimumab; 2 week washout for etanercept; 1 week washout for anakinra. If an IS agent is continued, the dose must remain ...

  5. Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease - Mayo Clinic

    Maintenance monotherapy: infliximab (at least 8 every 8 weeks), golilumumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least ...

  6. A Study to Assess the Effectiveness and Safety of Golimumab in Pediatric Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information. Participating ...

  7. A Study to Evaluate the Accuracy of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    Participation eligibility · biologic therapy targeted at tumor necrosis factor alpha (eg, infliximab, adalimumab, golimumab, etanercept, certolizumab); ...

  8. A Study to Evaluate the Effectiveness and Safety of PCS499 in Treating Ulcerations in Patients who have Necrobiosis Lipoidica - Mayo Clinic

    Current or previous (within 12 weeks of Baseline) treatment with any biologic therapy (e.g., adalimumab, etanercept, infliximab, anakinra, etc.).

  9. IBD Biobank Study

    Mayo Clinic's IBD Biobank Study collects biological samples & medical information to advance research on inflammatory bowel disease, Crohn's disease & other ...

  10. Impact of Surgical Removal or Reduction Procedures on Markers of Immune Function in Adult Patients with Renal and Bladder Tumors and Pediatric Patients with Genitourinary Tumors - Mayo Clinic

    infliximab), chemotherapy) or imunosuppressive condition (ex. transplant, immunodeficiency syndromes, HIV/AIDS); Auto-immune disease (ex. lupus, rheumatoid ...